Mortality Outcome of Controlled Hypertension (NCT07187596) | Clinical Trial Compass
Active — Not RecruitingNot Applicable
Mortality Outcome of Controlled Hypertension
Thailand2,547 participantsStarted 2025-09-18
Plain-language summary
This pooled analysis investigates mortality and severe adverse outcomes in patients with pharmacologically treated and blood pressure-controlled hypertension. Although blood pressure control is the primary goal of hypertension management, some patients continue to experience fatal cardiovascular, cerebrovascular, renal, or unexplained syndromes despite achieving treatment targets. The study aims to identify factors associated with these outcomes and to explore potential contributors beyond blood pressure measurements alone.
Literature identification is being conducted using a predefined search strategy based on Medical Subject Headings (MeSH) and relevant free-text keywords related to hypertension, mortality, cardiovascular disease, cerebrovascular disease, renal disease, and associated cardiometabolic conditions. The initial PubMed search yielded 9,298 records. Retrieved studies are undergoing systematic screening and eligibility assessment according to the study protocol. Eligible studies will subsequently undergo full-text review, quality appraisal, and pooled analysis.
Who can participate
Age range
1 Minute – 130 Years
Sex
ALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion criteria
* Human studies (RCTs, cohort, case-control, registry studies, etc.) declare participants with treated and controlled hypertension manage (regardless of drug class, duration, or comorbidity) reported mortality outcomes: all-vascular death, cardiovascular death, sudden death, etc.
* Studies in any setting (outpatient, inpatient, long-term follow-up)
* Articles in English
* Full-text available
Exclusion criteria
* Animal specimen or parameter studies
* Uncontrolled studies (e.g., case series without control, phase I safety trials)
* No mortality endpoint reported
* Purely mechanistic studies or trials that do not address BP or survival directly
* Pediatric studies unless separated subgroup for treated hypertension is available
* Glaucoma or portal hypertension or Pulmonary Hypertension without essential/systemic hypertension outcomes
* Infection without direct declare that septic shock or immunological failure associated by vascular cause from systemic hypertension
* Secondary/post-hoc analyses that do not report original mortality data
Questions worth asking your doctor
Bring these to your next appointment. They're a starting point for a shared conversation — not a sign you qualify or a recommendation to enrol.
1Since this study is actively collecting data but no longer enrolling new participants, is there any chance I could still be considered, or are there similar ongoing studies on controlled hypertension and vascular mortality that I might be eligible for?
2This trial is measuring all-cause vascular mortality across serious conditions like stroke, arterial aneurysm, and renal disease — what does that tell us about how my own blood pressure control might affect my long-term risk for these outcomes?
3The trial covers a wide range of hypertension-related complications including pre-eclampsia and arterial rupture — given my specific situation, which of these complications should we be most focused on monitoring or preventing?
4Since this study is listed as Phase NA, which often means it's observational rather than testing a new treatment, does participating in or following the findings of a study like this actually change the treatment options available to me, or would standard hypertension management still be the recommended path?
5Once results from this study on vascular mortality and controlled hypertension become available, how might those findings influence the blood pressure targets or medications my care team recommends for me?
Generated to help you prepare — always confirm anything about your own eligibility and care with the study team and your doctor.
Questions for the trial coordinator
The trial coordinator is the person who runs the study day to day. These cover the practical side — logistics, costs, and what taking part would actually mean for your life. The study team confirms whether you meet the criteria; these are questions to ask, not a sign you qualify.
1What does taking part actually involve week to week — how many visits, where, and how long does each one take?
2What costs are covered by the study, and what might I have to pay for myself, including travel, parking, or time off work?
3What happens during screening, and what happens if the study team confirms I don't meet the criteria after those tests?
4Who pays for the scans, blood work, and other tests the trial requires — the study, my insurance, or me?
5How will being in the trial affect my regular care, and will my own doctor stay informed and involved?
6Can I leave the trial at any point if I change my mind, and what would happen to my care if I do?
A starting point for the conversation — always confirm anything about your own eligibility, costs, and care with the study team and your doctor.
What they're measuring
1
All-cause vascular mortality
Timeframe: Day one until last follow up at least 24 hour to study completion date at least 30 days outcomes but not over 10 years